738P Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC).
Authors
Corrie, PQian, W
Gopinathan, A
Williams, M
Brais, R
Valle, Juan W
Basu, B
Falk, S
Iwuji, C
Wasan, H
Palmer, D
Scott-Brown, M
Wadsley, J
Arif, S
Bax, L
Bundi, P
Skells, R
Neesse, A
Tuveson, D
Jodrell, D
Affiliation
Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, CambridgeIssue Date
2017-09
Metadata
Show full item recordCitation
738P Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC). 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx369.121Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx369.121/4108824/738PStrong-tumour-cytidine-deaminase-CDA-stainingType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx369.121